BioLight Life Sciences (BioLight Life Sciences) Momentum Rank : 0 (As of Apr. 28, 2024)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Momentum Rank?

BioLight Life Sciences has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

BioLight Life Sciences Momentum Rank Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.